We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

81 hedge funds and large institutions have $339M invested in Enanta Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,333% more call options, than puts

Call options by funds: $412K | Put options by funds: $12K

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

158% more capital invested

Capital invested by funds: $132M → $339M (+$208M)

123% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 13

23% more funds holding

Funds holding: 66 → 81 (+15)

19% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 21

Holders
81
Holders Change
+15
Holders Change %
+22.73%
% of All Funds
2.34%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.09%
New
29
Increased
25
Reduced
21
Closed
13
Calls
$412K
Puts
$12K
Net Calls
+$400K
Net Calls Change
+$400K

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$56M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$42.5M
3
EAM
Eagle Asset Management
Florida
+$19.2M
4
CCM
Consonance Capital Management
New York
+$14.6M
5
ICRM
Insight Capital Research & Management
California
+$7.51M

Top Sellers

1
Franklin Resources
Franklin Resources
California
-$8.16M
2
AP
AlpInvest Partners
Netherlands
-$4.49M
3
SM
Sabby Management
Florida
-$3.12M
4
Millennium Management
Millennium Management
New York
-$2.93M
5
Barclays
Barclays
United Kingdom
-$2.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$98.7M +$42.5M +1,169,232 +90%
RCM
2
RA Capital Management
Massachusetts
$61.6M +$56M +1,541,078 New
CCM
3
Consonance Capital Management
New York
$50.2M +$14.6M +403,165 +47%
EAM
4
Eagle Asset Management
Florida
$21.2M +$19.2M +529,343 New
WSA
5
Wall Street Associates
California
$8.66M -$1.95M -53,800 -20%
ICRM
6
Insight Capital Research & Management
California
$8.27M +$7.51M +206,863 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$6.7M +$4.3M +118,512 +241%
CCM
8
Cadence Capital Management
Massachusetts
$6.48M +$5.89M +162,100 New
SAM
9
Senzar Asset Management
New York
$5.64M -$703K -19,343 -12%
TI
10
Turner Investments
Pennsylvania
$4.81M +$900K +24,770 +26%
BFA
11
BlackRock Fund Advisors
California
$4.1M +$103K +2,844 +3%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$3.55M +$38.2K +1,051 +1%
BBA
13
Baker Bros. Advisors
New York
$3.24M -$1.02M -28,140 -26%
Barclays
14
Barclays
United Kingdom
$3.14M -$2.64M -72,584 -47%
B
15
Bailard
California
$2.97M -$602K -16,560 -18%
MAA
16
Managed Account Advisors
New Jersey
$2.96M +$2.69M +74,135 New
TCIM
17
TIAA CREF Investment Management
New York
$2.9M +$1.34M +36,976 +104%
EI
18
EAM Investors
California
$2.63M -$67.6K -1,862 -3%
QBFM
19
QS Batterymarch Financial Management
New York
$2.39M +$2.17M +59,800 New
Arrowstreet Capital
20
Arrowstreet Capital
Massachusetts
$2.39M +$2.17M +59,707 New
HAMF
21
Hatteras Alternative Mutual Funds
North Carolina
$2.36M +$1.49M +41,024 +229%
GPCM
22
Granite Point Capital Management
Massachusetts
$2.2M -$182K -5,000 -8%
Wells Fargo
23
Wells Fargo
California
$2.16M +$818K +22,513 +72%
Northern Trust
24
Northern Trust
Illinois
$2.05M -$82.6K -2,274 -4%
Allianz Asset Management
25
Allianz Asset Management
Germany
$2.03M +$1.84M +50,765 New
1
2 3 4

ENTA Hedge Fund Activity: Q1 2014 in Review

81 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2014, worth a combined $339M — up 158% from $132M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ENTA positions and 13 closed out — a net gain of 16 holders — while 25 added to existing stakes and 21 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $56M. The largest seller was Franklin Resources, exiting entirely with an estimated $8.16M sold.

  • 81 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2014, up from 66 in Q4 2013.
  • Funds reported $339M of Enanta Pharmaceuticals stock for Q1 2014, up 158% quarter-over-quarter.
  • 29 funds opened new Enanta Pharmaceuticals positions in Q1 2014 and 13 closed out, a net change of +16 holders.
  • The largest Enanta Pharmaceuticals buyer in Q1 2014 was RA Capital Management, an estimated $56M added.
  • The largest Enanta Pharmaceuticals seller in Q1 2014 was Franklin Resources, an estimated $8.16M sold.

Based on aggregated 13F filings for Q1 2014.